|
1.
|
Eskens FA: Angiogenesis inhibitors in
clinical development; where are we now and where are we going? Br J
Cancer. 90:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Folkman J: Tumor angiogenesis: therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Warren RS, Yuan H, Matli MR, et al:
Regulation by vascular endothelial growth factor of human colon
cancer tumorigenesis in a mouse model of experimental liver
metastasis. J Clin Invest. 95:1789–1797. 1995. View Article : Google Scholar
|
|
4.
|
Takahashi Y, Ellis LM and Mai M: The
angiogenic switch of human colon cancer occurs simultaneous to
initiation of invasion. Oncol Rep. 10:9–13. 2003.PubMed/NCBI
|
|
5.
|
Asahara T, Murohara T, Sullivan A, et al:
Isolation of putative progenitor endothelial cells for
angiogenesis. Science. 275:964–967. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Asahara T, Takahashi T, Masuda H, et al:
VEGF contributes to postnatal neovascularization by mobilizing bone
marrow-derived endothelial progenitor cells. EMBO J. 18:3964–3972.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Bocci G, Francia G, Man S, et al:
Thrombospondin 1, a mediator of the anti-angiogenic effects of
low-dose metronomic chemotherapy. Proc Natl Acad Sci USA.
100:12917–12922. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kerbel RS and Kamen BA: The
anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer.
4:423–436. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Monestiroli S, Mancuso P, Burlini A, et
al: Kinetics and viability of circulating endothelial cells as
surrogate angiogenesis marker in an animal model of human lymphoma.
Cancer Res. 61:4341–4344. 2001.PubMed/NCBI
|
|
10.
|
Bocci G, Nicolaou KC and Kerbel RS:
Protracted low-dose effects on human endothelial cell proliferation
and survival in vitro reveal a selective anti-angiogenic window for
various chemotherapeutic drugs. Cancer Res. 62:6938–6943.
2002.PubMed/NCBI
|
|
11.
|
Shaked Y, Emmenegger U, Man S, et al:
Optimal biologic dose of metronomic chemotherapy regimens is
associated with maximum anti-angiogenic activity. Blood.
106:3058–3061. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Shimada Y, Yoshino M, Wakui A, et al:
Phase II study of CPT-11, a new camptothecin derivative, in
metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study
group. J Clin Oncol. 11:909–913. 1993.PubMed/NCBI
|
|
13.
|
Rothenberg ML, Cox JV, deVore RF, et al: A
multicenter, phase II trial of weekly irinotecan (CPT-11) in
patients with previously treated colorectal carcinoma. Cancer.
85:786–795. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kim KJ, Li B, Winer J, et al: Inhibition
of vascular endothelial growth factor-induced angiogenesis
suppresses tumor growth in vivo. Nature. 362:841–844. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Gerber HP and Ferrara N: Pharmacology and
pharmacodynamics of bevacizumab as monotherapy or in combination
with cytotoxic therapy in preclinical studies. Cancer Res.
65:671–680. 2005.PubMed/NCBI
|
|
16.
|
Beaudry P, Force J, Naumov G, et al:
Differential effects of vascular endothelial growth factor
receptor-2 inhibitor ZD6474 on circulating endothelial progenitors
and mature circulating endothelial cells: implications for use as a
surrogate marker of anti-angiogenic activity. Clin Cancer Res.
11:3514–3522. 2005. View Article : Google Scholar
|
|
17.
|
Nitta K, Yokokura T, Sawada S, et al:
Antitumor activity of novel derivatives of camptothecin. Jpn J
Cancer Chemother. 14:850–857. 1987.
|
|
18.
|
Bertolini F, Paul S, Mancuso P, et al:
Maximum tolerable dose and low-dose metronomic chemotherapy have
opposite effects on the mobilization and viability of circulating
endothelial progenitor cells. Cancer Res. 63:4342–4346. 2003.
|
|
19.
|
Capillo M, Mancuso P, Gobbi A, et al:
Continuous infusion of endostatin inhibits differentiation,
mobilization, and clonogenic potential of endothelial cell
progenitors. Clin Cancer Res. 9:377–382. 2003.PubMed/NCBI
|
|
20.
|
Mizobe T, Ogata Y, Murakami H, et al:
Efficacy of the combined use of bevacizumab and irinotecan as a
postoperative adjuvant chemotherapy in colon carcinoma. Oncol Rep.
20:517–523. 2008.PubMed/NCBI
|
|
21.
|
Klement G, Baruchel S, Rak J, et al:
Continuous low-dose therapy with vinblastine and VEGF receptor-2
antibody induces sustained tumor regression without overt toxicity.
J Clin Invest. 105:R15–R24. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Browder T, Butterfield CE, Kraling BM, et
al: Anti-angiogenic scheduling of chemotherapy improves efficacy
against experimental drug-resistant cancer. Cancer Res.
60:1878–1886. 2000.PubMed/NCBI
|
|
23.
|
Colleoni M, Rocca A, Sandri MT, et al:
Low-dose oral methotrexate and cyclophosphamide in metastatic
breast cancer: antitumor activity and correlation with vascular
endothelial growth factor levels. Ann Oncol. 13:73–80. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
De Bont ES, Guikema JE, Scherpen F, et al:
Mobilized human CD34+ hematopoietic stem cells enhance
tumor growth in a nonobese diabetic/severe combined immunodeficient
mouse model of human non-Hodgkin’s lymphoma. Cancer Res.
61:7654–7659. 2001.
|
|
25.
|
Schuch G, Heymach JV, Nomi M, et al:
Endostatin inhibits the vascular endothelial growth factor-induced
mobilization of endothelial progenitor cells. Cancer Res.
63:8345–8350. 2003.PubMed/NCBI
|
|
26.
|
Twelves C; Xeloda Colorectal Cancer group:
Capecitabine as first-line treatment in colorectal cancer. Pooled
data from two large, phase III trials. Eur J Cancer. 38(Suppl. 2):
S15–S20. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Douillard JY, Hoff PM, Skillings JR, et
al: Multicenter phase III study of uracil/tegafur and peroral
leucovorin versus fluorouracil and leucovorin in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
20:3605–3616. 2002. View Article : Google Scholar
|
|
28.
|
Santini D, Vincenzi B, Schiavon G, et al:
Chronomodulated administration of oxaliplatin plus capecitabine
(XELOX) as first line chemotherapy in advanced colorectal cancer
patients: phase II study. Cancer Chemother Pharmacol. 59:613–620.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Goto A, Yamada Y, Yasui H, et al: Phase II
study of combination therapy with S-l and irinotecan in patients
with advanced colorectal cancer. Ann Oncol. 6:968–973. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kato H, Ichinose Y, Ohta M, et al: A
randomized trial of adjuvant chemotherapy with uracil-tegafur for
adenocarcinoma of the lung. N Engl J Med. 350:1713–1721. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Ogata Y, Sasatomi T, Mori S, et al:
Significance of thymidine phosphorylase in metronomic chemotherapy
using CPT-11 and doxifluridine for advanced colorectal carcinoma.
Anticancer Res. 27:2605–2612. 2007.PubMed/NCBI
|
